Calibration Technologies for Correct Determination of Epstein-Barr Virus, Human Herpesvirus 6 (HHV-6), and HHV-8 Antiviral Drug Susceptibilities by Use of Real-Time-PCR-Based Assays.

Calibration Technologies for Correct Determination of Epstein-Barr Virus, Human Herpesvirus 6 (HHV-6), and HHV-8 Antiviral Drug Susceptibilities by Use of Real-Time-PCR-Based Assays.

J Clin Microbiol. 2013 Jun; 51(6): 2013
Broccolo F, Lusso P, Malnati M

HubMed – drug

Efficacy and Safety of LB03002, a Once-Weekly Sustained-Release Human Growth Hormone for 12-Month Treatment in Korean Children with Growth Hormone Deficiency.

Eur J Endocrinol. 2013 May 16;
Hwang JS, Lee HS, Chung WY, Han HS, Jin DK, Kim HS, Ko CW, Lee BC, Lee DY, Lee KH, Shin JH, Suh BK, Yoo HW, Ji HJ, Lee JH, Bae YJ, Kim DH, Yang SW

PURPOSE: The purpose of this study was to investigate the efficacy and safety of LB03002, a sustained-release growth hormone (SR-hGH), compared to that of daily rhGH for 12 months in children with growth hormone deficiency. METHODS: Total of 73 children with growth hormone deficiency (GHD) were screened and 63 eligible subjects were randomized in a 1:1 ratio to LB03002 (sustained-release human growth hormone, SR-hGH) or daily rhGH treatment group. LB03002 was administered once weekly at a dose of 0.5 mg/kg while daily hGH was administered for 6 consecutive days with the equally divided doses to make a total of 0.21 mg/kg/wk. Treatments were administered for 12 months by subcutaneous injections. Injection site reactions and adverse events were investigated throughout the study period. RESULTS: The mean (standard deviation, SD) height velocity (HV) showed clinically significant increase after 6-month treatment: 3.00 (1.15) cm/year at screening to 9.78 (1.98) cm/year at 6-month in LB03002 group; 2.39 (1.63) cm/year at screening to 10.56 (2.65) cm/year at 6-month in daily hGH group. Increased HV at 12-month was still maintained in both groups: 9.06 (1.63) cm/year at 12 month in LB03002 group; 9.72 (2.32) cm/year at 12 month in daily rhGH group. Most of the adverse drug reactions were mild and tolerable. No subjects were withdrawn due to adverse events. CONCLUSION: Weekly injection of LB03002 at a dose of 0.5 mg/kg/wk was confirmed to have comparable efficacy to daily injection of daily rhGH at a dose of 0.21 mg/kg/wk. Both formulations were well tolerated. HubMed – drug

Aceclofenac-induced acute tubulointerstitial nephritis in a patient with diabetes.

BMJ Case Rep. 2013; 2013:
Gupta M, Cruz SD, Nada R, Aggarwal P

We describe a case of a 40-year-old lady diabetic and hypertensive, who presented with increasing fatigue and decreased physical endurance attributable to deterioration in renal function. The renal biopsy revealed drug-induced acute tubulointerstitial nephritis and the chronology of the events suggested the aetiology to be a recent intake of aceclofenac for knee pain. The patient improved with oral corticosteroids and the renal functions returned to baseline in 3 weeks. We did not come across a case of aceclofenac-induced acute tubulointerstitial nephritis on extensive electronic search of literature. This is probably the first case report of acute tubulointerstitial nephritis associated with the use of aceclofenac, a newer potent non-steroidal anti-inflammatory drug. HubMed – drug